News & Updates
Filter by Specialty:
Levonorgestrel-releasing intrauterine system reduces pelvic pain but may increase expulsion risk
06 Sep 2022
In the treatment of patients with organic disease and heavy menstrual bleeding and/or dysmenorrhea, the use of levonorgestrel-releasing intrauterine system (LNG-IUS) attenuates chronic pelvic pain, according to a study. However, it appears to confer an increased risk of expulsion for some women.
Levonorgestrel-releasing intrauterine system reduces pelvic pain but may increase expulsion risk
06 Sep 2022
Brolucizumab noninferior to aflibercept in nAMD
03 Sep 2022
Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.